COMP <GO>
INMD vs UNH // REVENUE GROWTH (YOY)
InMode Ltd. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: INMD 5
— UNH 6
▲ REVENUE GROWTH (YOY) LEADER: UNH
LAST: $13.51 (+1.05%) • MKT CAP: $776.6M
revenue-growth
-6.20%
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
revenue-growth
6.46%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INMD VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INMD | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.50% | 88.57% | -10.07 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.70% | 11.47% | +6.23 | INMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.5x | 16.4x | -10.95 | INMD | /valuation <GO> |
| Free Cash Flow Yield | 10.85% | 6.48% | +4.37 | INMD | /fcf-yield <GO> |
| Operating Margin | 23.00% | 4.82% | +18.18 | INMD | /operating-margins <GO> |
| Net Profit Margin | — | 3.14% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -6.20% | 6.46% | -12.66 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.20 | 3.12 | +6.08 | INMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.3 | 59.2 | -22.90 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $776.6M | $368.83B | -$368.05B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INMD REV | UNH REV | INMD GROSS % | UNH GROSS % | INMD FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $370.5M | $447.57B | 78.5% | 88.7% | $84.3M | $16.07B |
| FY 2024 | $394.8M | $400.28B | 80.3% | 88.3% | $132.0M | $20.70B |
| FY 2023 | $492.0M | $371.62B | — | 89.6% | $176.8M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INMD // BETA —
UNH // BETA 0.33